News & Updates

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.

For patients who have undergone coronary artery bypass graft, initiating treatment with sacubitril/valsartan early is safe and appears to improve outcomes, as shown in an open-label study.

An international team of experts has identified 13 promising biomarkers to predict cardiovascular disease (CVD) risk in patients with type 2 diabetes mellitus (T2DM), of which N-terminal pro-brain natriuretic peptide (NT-proBNP) has shown the highest predictive utility with highest strength of evidence.

An elevated systolic blood pressure (BP) variability (BPV) in healthy older adults may lead to a higher risk of frailty regardless of their mean BP, suggests a study.

Patients with chronic obstructive pulmonary disorder (COPD) face a heightened risk of adverse cardiovascular events following moderate or severe exacerbations, according to a study.